Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia (ACCESS)

A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial

Traditional management of community-acquired pneumonia (CAP) relies on the prompt administration of antimicrobials that target the most common causative pathogens. Retrospective analysis of observational clinical studies in CAP showed that the addition of macrolides to standard antibiotic therapy conferred a significant survival benefit. The proposed benefit of macrolides is coming from their anti-inflammatory mode of action. An RCT that proves the attenuation of the high inflammatory burden of the host with CAP after addition of clarithromycin in the treatment regimen is missing. This RCT is aiming to prove that addition of oral clarithromycin to a β-lactam rapidly attenuates the high inflammatory burden of the host in CAP.

Study Overview

• Status: Completed
• Conditions: Sepsis; Mortality; Inflammatory Response; Biomarkers; SIRS; Community-acquired Pneumonia
• Intervention / Treatment: Drug: Tablets; Drug: Clarithromycin 500mg

Detailed Description

Community-acquired pneumonia (CAP) is one of the most common bacterial infections and a leading cause of death globally since many patients deteriorate into sepsis and organ dysfunction. Traditional management relies on the prompt administration of antimicrobials that target the most common causative pathogens namely Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila. Although there was some hesitancy in the former guidelines of the Infectious Diseases Society of America (IDSA) and of the American Thoracic Society (ATS) to suggest a clear-cut role of macrolides for the management of CAP, the new guidelines published by the ATS in 2019 clearly suggest for the management of all cases of CAP either treated as out-patients or as in-patients with a combination of β-lactam with macrolides.

The shift in the position of ATS expressed in the 2019 guidelines is coming from the growing body of evidence that the addition of a macrolide in the treatment regimen of CAP is accompanied by considerable survival benefit. This finding is mainly coming from the retrospective analysis of observational clinical studies in CAP. Results were also supported by the meta-analysis of these studies . Superiority coming from the macrolide use is mainly shown in cases of severe CAP i.e. situations with pneumonia severity index (PSI) greater than 2 that are most commonly caused by S.pneumoniae. The proposed benefit of macrolides is coming from their anti-inflammatory mode of action. This statement generates two main questions: a) what an anti-inflammatory mode of action consists of in the clinical setting; and b) is this a common property for all macrolides? Although it is easy to suggest that an antimicrobial modulates immune responses in vitro, it is extremely difficult to prove this in vivo. The main hurdle is coming from the fact that it is difficult to decipher to what extent clinical benefit is coming from the antimicrobial effect per se and to what extent this is due to modulation of the immune responses. In other terms, an anti-inflammatory effect is better shown in infections caused by pathogens that do not belong to the antimicrobial spectrum of macrolides. Our group has conducted two large scale randomized clinical trials (RCTs) where clarithromycin was co-administered intravenously along with β-lactams in either patients with ventilator-associated pneumonia (VAP) by multidrug-resistant Gram-negative pathogens or patients with severe Gram-negative infections like acute pyelonephritis, intraabdominal infections and primary Gram-negative bacteremia. The total number of patients enrolled in both studies was 800 and isolated pathogens did not belong to the antimicrobial spectrum of macrolides. Addition of clarithromycin provided overall survival benefit after 90-days in patients with VAP (57% survival versus 40% of placebo-treated comparators). Mortality by septic shock after 28-days was also considerably decreased in patients with severe Gram-negative infections (53.1% versus 73.1% of the comparators).

Although these findings point towards an anti-inflammatory mode of action of clarithromycin, they do not necessarily imply that a survival benefit similar to Gram-negative infections will apply in CAP. There is only one RCT to test the anti-inflammatory effect of clarithromycin in patients with CAP. This RCT was designed for non-inferiority and randomized patients were allocated into single β-lactam treatment or the combination with oral clarithromycin. The primary endpoint was clinical instability after seven days. Contrary to what investigators were expecting this was shown in 41.2% of non-macrolide treated patients and 33.6% of macrolide-treated patients (p: 0.070). It may be argued that if the study was powered for superiority, the study primary endpoint would have shown benefit from the addition of clarithromycin.

In recent publication coming from the research network of the Hellenic Sepsis Study Group (HSSG) 130 patients with CAP were treated with a combination of β-lactam and clarithromycin. They were compared with another 130 patients treated with a combination of β-lactam and azithromycin, with 130 patients treated with respiratory fluoroquinolone monotherapy and with 130 treated with β-lactam monotherapy. The study has a case-matching design and selection of cases of the three comparator groups were based on the group of patients treated with clarithromycin. Matching selection criteria were severity as assessed by the severity score of SOFA (sequential organ failure assessment), APACHE II (acute physiology and chronic health evaluation), PSI and CCI (Charlson's comorbidity index) and type of β-lactam. The 28-day mortality of the four groups was 20.8%, 33.8%, 32.3% and 36.2% respectively, showing a profound survival benefit with the intake of clarithromycin.

Based on the above analysis, it seems likely that an RCT that proves the attenuation of the high inflammatory burden of the host with CAP after addition of clarithromycin in the treatment regimen is missing. The need for this RCT is outscored in the recent guidelines of ATS . Such a type of RCT should take into consideration the SOFA score of the patients, the presence of the systemic inflammatory response syndrome (SIRS), the existence of elevated procalcitonin (PCT) in serum and the outcome of patients infected by macrolide-resistant S.pneumoniae. SOFA score is nowadays proposed as the sine qua non for severity. PCT more than 0.25 ng/ml is widely accepted as an index of systemic inflammation in the event of CAP to such an extent that decrease more than 80% or to levels lower than 0.25 ng/ml can be used as an index of therapy withdrawal. In such an RCT rapid resolution of the high inflammatory burden of the host should be highlighted in the achievement of the early treatment response of CAP after 72 hours that is recently appointed by the Food and Drug Administration and the European Medicines Agency as the primary endpoint goal of CAP.

This is an RCT that is aiming to prove that addition of oral clarithromycin to a β-lactam rapidly attenuates the high inflammatory burden of the host in CAP.

• Study Type: Interventional
• Enrollment (Actual): 278
• Phase: Phase 3

Contacts and Locations

Study Locations

• Greece
  • Athens, Greece, 12462
    • 4th Department of Internal Medicine, Attikon University Hospital
  • Athens, Greece
    • 1st Department of Internal Medicine, Amalia Fleming General Hospital
  • Athens, Greece
    • 1st Department of Internal Medicine, Gennimatas General Hospital
  • Athens, Greece
    • 1st Department of Internal Medicine, Konstantopouleio-Patission General Hospital
  • Athens, Greece
    • 1st Department of Internal Medicine, THRIASIO Eleusis General Hospital
  • Athens, Greece
    • 1st Department of Internal Medicine,Korgialeneio-Benakeio General Hospital
  • Athens, Greece
    • 2nd Department of Internal Medicine, Attikon University Hospital
  • Athens, Greece
    • 2nd Department of Internal Medicine, Thriasio General Hospital
  • Athens, Greece
    • 3rd Department of Internal Medicine, KORGIALENEION-BENAKEION Athens General Hospital
  • Athens, Greece
    • 3rd Department of Internal Medicine, Sotiria General Hospital
  • Athens, Greece
    • 5th Department of Internal Medicine, Evangelismos General Hospital
  • Athens, Greece
    • Department of Chest Medicine, EVANGELISMOS Athens General Hospital
  • Corfu, Greece
    • Department of Pulmonary Medicine, General Hospital of Kerkyra
  • Ioannina, Greece
    • 1st Department of Internal Medicine, Ioannina University General Hospital
  • Larissa, Greece
    • Department of Internal Medicine, Larissa University General Hospital
  • Patra, Greece
    • Department of Internal Medicine, Patras University General Hospital
  • Piraeus, Greece
    • Department of Emergency Medicine, Tzanneion General Hospital
  • Piraeus, Greece
    • 2nd Department of Internal Medicine, Tzaneion General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult patients (≥18 years)
• Male of female gender
• In case of non-menopausal women, unwillingness to become pregnant during the study period. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study.
• Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent
• Presence of at least two signs of SIRS (see below for definition)
• SOFA score ≥2 (see Appendix I)
• PCT ≥0.25 ng/ml
• Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain
• Presence of CAP (see below for definition)

SIRS is defined by the presence of at least two of the following criteria:

• Core temperature >38 Celsius degrees or <36 Celsius degrees
• Heart rate >90 beats/minute
• Breath rate >20 breaths/minute or pco2<32 mmHg
• Total white blood cell count >12,000/mm3 or <4,000/mm3 or >15% bands

CAP is defined as the presence of auscultatory findings compatible with CAP and new consolidation in chest X-ray in a patient without any history of contact with the hospital environment or with health-care facilities the last 90 days.

Exclusion Criteria:

• Age below 18 years
• Denial of written informed consent
• Presence of infection by SARS-CoV-2 (COVID-19)
• Intake of any macrolide for the current episode of CAP under study
• Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 15 days
• Neutropenia defined as an absolute neutrophil count below 1,000/mm3
• Known infection by the human immunodeficiency virus
• Any chronic anti-cytokine treatment (e.g. antibodies against TNF for rheumatoid arthritis)
• Hospitalization for more than 2 days the last 90 days
• QTc interval at rest ECG ≥500 msec or history of known congenital long QT syndrome
• Concomitant administration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), and presence of any contraindications for the study drug
• Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.	Drug: Tablets; Oral tablets of similar appearance to active study drug; Other Names: 2g of intravenous ceftriaxone or one β-lactam/β-lactamase combination(dose adjusted according to renal clearance) or 400mg of intravenous moxifloxacin
Active Comparator: Clarithromycin; These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.	Drug: Clarithromycin 500mg; Oral tablets of 500mg of clarithromycin; Other Names: 2g of intravenous ceftriaxone or one β-lactam/β-lactamase combination(dose adjusted according to renal clearance) or 400mg of intravenous moxifloxacin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of baseline respiratory symptoms score	At least 50 percent (%) decrease of the sum of scoring (0-12) for the symptoms of cough (0-3), dyspnea (0-3), purulent sputum expectoration (0-3) and pleuritic chest pain (0-3) between baseline and Study Day 4	4 days
Change of baseline total sequential organ failure assessment (SOFA) score and/or change of baseline serum PCT	At least 30 percent (%) decrease between baseline sequential organ failure assessment (SOFA) score and measured sequential organ failure assessment (SOFA) score at Study Day 4 and/or at least 80 percent (%) decrease of serum PCT from baseline PCT at Study Day 4 and/or serum PCT below 0.25 ng/ml at Study Day 4	4 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of baseline respiratory symptoms score in the subgroup of patients infected or colonized by clarithromycin-susceptible S.pneumoniae	Comparison of the number of patients reaching at least 50 percent (%) decrease of the sum of scoring (0-12) for the symptoms of cough (0-3), dyspnea (0-3), purulent sputum expectoration (0-3) and pleuritic chest pain (0-3) between baseline and Study Day 4, among clarithromycin and placebo-treated patients, infected or colonized by clarithromycin-susceptible S.pneumoniae	4 days
Change of baseline respiratory symptoms score in the subgroup of patients infected or colonized by clarithromycin-resistant S.pneumoniae	Comparison of the number of patients reaching at least 50 percent (%) decrease of the sum of scoring (0-12) for the symptoms of cough (0-3), dyspnea (0-3), purulent sputum expectoration (0-3) and pleuritic chest pain (0-3) between baseline and Study Day 4, among clarithromycin and placebo-treated patients, infected or colonized by clarithromycin-susceptible S.pneumoniae	4 days
Change of baseline total sequential organ failure assessment (SOFA) score and/or change of baseline serum PCT in the subgroup of patients infected or colonized by clarithromycin-susceptible S.pneumoniae	Comparison of the number of patients reaching at least 30 percent (%) decrease between baseline sequential organ failure assessment (SOFA) score and measured sequential organ failure assessment (SOFA) score at Study Day 4 and/or at least 80 percent (%) decrease of serum PCT from baseline at Study Day 4 and/or serum PCT below 0.25 ng/ml at Study Day 4, among clarithromycin and placebo-treated patients infected or colonized by clarithromycin-susceptible S.pneumoniae	4 days
Change of baseline total sequential organ failure assessment (SOFA) score and/or change of baseline serum PCT in the subgroup of patients infected or colonized by clarithromycin-resistant S.pneumoniae	Comparison of the number of patients reaching at least 30 percent (%) decrease between baseline sequential organ failure assessment (SOFA) score and measured sequential organ failure assessment (SOFA) score at Study Day 4 and/or at least 80 percent (%) decrease of serum PCT from baseline at Study Day 4 and/or serum PCT below 0.25 ng/ml at Study Day 4, among clarithromycin and placebo-treated patients infected or colonized by clarithromycin-resistant S.pneumoniae	4 days
Mortality rate at 28 days	Differences in 28-day all-cause mortality rate between clarithromycin and placebo-treated arms	28 days
Mortality rate at 90 days	Differences in 90-day all-cause mortality rate between clarithromycin and placebo-treated arms	90 days
Clinical success at the end of treatment Visit (day 8)	Difference in clinical success rate at day 8, as defined by at least 50 percent (%) decrease of the baseline sum of scoring (0-12) for the symptoms of cough (0-3), dyspnea (0-3), purulent sputum expectoration (0-3) and pleuritic chest pain (0-3)	8 days
Hospital discharge until day 90	Comparison of length of hospital stay (days) until day 90 between clarithromycin and placebo-treated arms	90 days
Hospital readmission until day 90	Comparison of hospital readmission rate until day 90 between clarithromycin and placebo-treated arms	90 days
Change of baseline total sequential organ failure assessment (SOFA) score at the end of treatment Visit (day 8)	Comparison of number of patients reaching more than 50 percent (%) decrease between baseline sequential organ failure assessment (SOFA) score and measured sequential organ failure assessment (SOFA) score at Study Day 8 between clarithromycin and placebo-treated arms	8 days
Development of new organ dysfunctions until day 90	Comparison of the rate of development of new organ dysfunctions between clarithromycin and placebo-treated arms	90 days
Change of function of monocytes, Th1, Th2 and T17 cells at Study Visit 4	Comparison of cytokine production by stimulation of monocytes, Th1,Th2 and T17 cells between clarithromycin and placebo-treated arms	4 days
Change of gene expression of anti-inflammatory genes at Study Visit 4	Comparison of the expressions of four genes (FGL-2, IL7R, HLA-DPA1, CPVL), that are down-regulated upon development of severe infections, between clarithromycin and placebo-treated arms	4 days
Anti-inflammatory PCT change at study Visit 6	Comparison of number of patients reaching at least 80 percent (%) decrease of serum PCT from baseline on day 6 or any value of PCT below 0.25 ng/ml on day 6 between clarithromycin and placebo-treated arms	6 days
Anti-inflammatory PCT change at the end of treatment Visit (day 8)	Comparison of number of patients reaching at least 80 percent (%) decrease of serum PCT from baseline on day 8 or any value of PCT below 0.25 ng/ml on day 8 between clarithromycin and placebo-treated arms	8 days
Change of the IL-10/TNFα ratio at study Visit 6	Comparison of the change of the IL-10/TNFα ratio between baseline and day 6 among clarithromycin and placebo-treated arms	6 days
Change of the IL-10/TNFα ratio at the end of treatment Visit (day 8)	Comparison of the of the change of the IL-10/TNFα ratio between baseline and day 8 among clarithromycin and placebo-treated arms	8 days
New sepsis episode until day 90	Comparison of the rate of development of new sepsis episode between clarithromycin and placebo-treated arms	90 days
Change of expression of the MVK gene at study Visit 4	Comparison of the expression of the MVK gene, that affects the cholesterol homeostasis pathway, between clarithromycin and placebo-treated arms	4 days
Change of expression of the SC5D gene at study Visit 4	Comparison of the expression of the SC5D gene, that affects the cholesterol homeostasis pathway, between clarithromycin and placebo-treated arms	4 days
Change of expression of the MVD gene at study Visit 4	Comparison of the expression of the MVD gene, that affects the cholesterol homeostasis pathway, between clarithromycin and placebo-treated arms	4 days
Change of expression of the STARD4 gene at study Visit 4	Comparison of the expression of the STARD4 gene, that affects the cholesterol homeostasis pathway, between clarithromycin and placebo-treated arms	4 days
Change of expression of the SQLE gene at study Visit 4	Comparison of the expression of the SQLE gene, that affects the cholesterol homeostasis pathway, between clarithromycin and placebo-treated arms	4 days

Collaborators and Investigators

• Sponsor: Hellenic Institute for the Study of Sepsis
• Investigators: Study Chair: Evangelos J Giamarellos-Bourboulis, MD, Phd, Hellenic Sepsis Study Group

Study record dates

Study Major Dates

• Study Start (Actual): January 25, 2021
• Primary Completion (Actual): April 11, 2023
• Study Completion (Actual): April 11, 2023

Study Registration Dates

• First Submitted: January 20, 2021
• First Submitted That Met QC Criteria: January 22, 2021
• First Posted (Actual): January 26, 2021

Study Record Updates

• Last Update Posted (Actual): December 12, 2023
• Last Update Submitted That Met QC Criteria: December 10, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Clarithromycin; Macrolides
• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Protein Synthesis Inhibitors; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptives, Oral, Combined; Contraceptives, Oral; Contraceptive Agents, Female; Moxifloxacin; Ceftriaxone; Norgestimate, ethinyl estradiol drug combination; Clarithromycin; Lactams; beta-Lactams
• Other Study ID Numbers: ACCESS; 2020-004452-15 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No